低分子肝素治疗胎儿生长受限的临床疗效

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (23 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the effect of low molecular weight heparin(LMWH)in the treatment of fetal growth restriction(FGR).Methods A total of Fifty pregnant women with FGR who were diagnosed and treated in Shenzhen Luohu District of Maternal and Child Health Hospital fromJuly 2016 and August 2017 were selected as the research subjects.They were divided into control group and study group by the random number table method,25 cases in each group.The control group was given conventional treatment,and the the study group was given conventional treatment and treatment with LMWH.Fetal growth,umbilical blood flow and adverse reactions were observed in both groups.Results The increased values of maternal fundal height,abdominal circumference,and fetal growth in study group were higher than those in control group,the differences were statistically significant(P＜0.05).Differences in fetal pulsatility index(PI）,resistance index(RI)or umbilical artery systolic and diastolic blood flow velocity ratio(S/D))between the two groups were not statistically significant before treatment(P＞0.05).After treatment,the PI,RI and S/D in both groups were lower than those of the control group,PI,RI and S/D in study group were lower than those in the control group after treatment,the differences were statistically significant(P＜0.05).There was no significant difference in the incidence rate of adverse reactions between the two groups(P＞0.05).Conclusion Treatment with LMWH for FGR can effectively improve fetal umbilical artery blood flow and promote fetal growth and development.However,due to the particularity of pregnant women,it is necessary to strengthen nursing during medication to ensure the curative effect and safety.

Key words： Low molecular weight heparin Fetus Growth restriction

Received: 23 March 2020

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I2/37

[5]	陈永利.阿斯匹林联合低分子肝素治疗胎儿生长受限的临床疗效及对胎儿血流参数变化母婴结局的影响[J].河北医学，2019，25（3）：691-695.
[6]	黄赟博，刘倩倩，余艳红.胎儿生长受限与血管生成因子的关系[J].南方医科大学学报，2014，34（7）：1068-1070.
[7]	徐慧芳，李道成，雷友金，等.益气养血活血法治疗胎儿生长受限对孕妇血液流变学的影响[J].中国中医基础医学杂志，2014，20（8）：1104-1106.
[8]	朱薏.低分子肝素联合主动免疫治疗不明原因复发性自然流产的效果[J].实用医学杂志，2015，31（5）：793-795.
[4]	吴婷，罗力冰.低分子肝素对胎儿生长受限孕妇血栓前状态的改善作用[J].中国临床研究，2015，28（3）：353-355.
[9]	芮璨，宋学静，龙伟，等.低分子肝素治疗子痫前期合并胎儿生长受限对妊娠结局的影响[J].江苏医药，2015，41（16）：1887-1890.
[10]	章茜，姜纬.低分子肝素联合低分子右旋糖酐治疗胎儿宫内生长受限的效果观察[J].山东医药，2014，54（45）：73-74.
[11]	江志发，许燕滨，胡慧珍，等.低分子肝素早期干预治疗胎儿生长受限的临床效果监测[J].热带医学杂志，2019，19（6）：781-784，810.
[12]	严文彦，卢纹，欧燕珊.胎儿宫内生长受限采用低分子肝素治疗的临床效果分析[J].中国病案，2019，20（2）：102-104.
[1]	乔娟，漆洪波.胎儿生长受限：更新的认识[J].中华围产医学杂志，2015，18（6）：418-420.
[2]	阮焱，王欣.320 例胎儿生长受限临床分析[J].医学综述，2015，21（7）：1287-1289.
[3]	连文艳，陈倩，初晓丽.胎儿生长受限与脐血流比值及孕妇红细胞压积的关系研究[J].中国计划生育和妇产科，2014，6（4）：55-58.
[13]	黄捷，吴华璋，陈若子，等.低分子肝素治疗胎儿生长受限的护理干预[J].中国现代医生，2014，52（15）：102-104.
[14]	黄秀娟，宋娟，朱锦渊，等.早期运动干预对胎儿生长受限儿的疗效观察[J].中国儿童保健杂志，2016，24（7）：767-769.
[15]	艳爱，陈晖，刘杏仙，等.低分子肝素联合护理干预在胎儿生长受限中的应用[J].齐鲁护理杂志，2015，21（11）：79-81.